Crism Therapeutics Corporation

1. 21 Sep 26
   Half-year Results

   (“CRISM”, “CRISM Therapeutics”, the “Company” or the “Group”)

   RNS 9780752 ↗
2. 17 Sep 26
   Appointment of Non-executive Chair

   CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce the appointment of Dr Charles Spicer as Non-Executive Chair with effect from...

   RNS 9776271 ↗
3. 20 Aug 26
   Commencement of Patient Recruitment

   596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.

   RNS 9732148 ↗
4. 13 Aug 26
   Clinical Trial Update

   596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.

   RNS 9719016 ↗
5. 27 Jul 26
   Result of Shareholder Analysis

   CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third-party shareholder register...

   RNS 9687766 ↗
6. 26 Jun 26
   Final Results

   'Regulatory milestones achieved and well-funded to advance Phase 2 Clinical Trial'

   RNS 9637886 ↗
7. 25 Jun 26
   Phase 2 Clinical Trial Progress Update

   596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.

   RNS 9635384 ↗
8. 04 Jun 26
   Significant Grant Award

   596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.

   RNS 9600723 ↗
9. 01 Jun 26
   Grant Award

   596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.

   RNS 9593417 ↗
10. 28 May 26
    Result of Retail Offer

    This Announcement does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any investment decision in respect of CRISM Therapeutics Corporation or other evaluation of any...

    RNS 9590417 ↗
11. 26 May 26
    Retail Offer to raise up to £100,000

    CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce a retail offer via BookBuild (the "Retail Offer") of new ordinary shares...

    RNS 9584267 ↗
12. 26 May 26
    Placing of £2.5 million

    This Announcement does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any investment decision in respect of CRISM Therapeutics Corporation or other evaluation of any...

    RNS 9583883 ↗
13. 21 Apr 26
    Positive Preclinical Data for Docetaxel ChemoSeed

    596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.

    RNS 9529231 ↗
14. 02 Apr 26
    Directorate Change

    596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.

    RNS 9504435 ↗
15. 25 Mar 26
    Phase 2 Clinical Trial Progress Update

    596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.

    RNS 9490199 ↗
16. 17 Mar 26
    Awarding of Orphan Drug Designation by the FDA

    596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.

    RNS 9477015 ↗
17. 20 Jan 26
    Japanese Patent Grant

    CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has been granted a patent (7800909) by the Japanese Patent Office.

    RNS 9367760 ↗
18. 09 Jan 26
    Results of Shareholder Analysis

    CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third-party shareholder register...

    RNS 9342889 ↗
19. 15 Dec 25
    Result of Retail Offer

    596/2014, AS INCORPORATED INTO UK LAW BY THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").

    RNS 9297795 ↗
20. 10 Dec 25
    Retail Offer

    CRISM Therapeutics Corporation (the "Company") is pleased to announce a retail offer via BookBuild (the "Retail Offer") of new ordinary shares ("Ordinary Shares") of nil par value each in the capital of the Company (the "Retail Offer Shares") at an issue...

    RNS 9287250 ↗
21. 10 Dec 25
    Placing of £1,000,000

    596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.

    RNS 9286613 ↗
22. 30 Oct 25
    US Orphan Drug Designation Application

    Submission of Orphan Drug Designation Application to the FDA for Irinotecan-ChemoSeed™ in Glioblastoma

    RNS 9202797 ↗
23. 14 Oct 25
    Positive Preclinical Data in Prostate Cancer

    596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.

    RNS 9168716 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.